OnePin Peptide Library · Weight
Frag 17-23
BPC-157 Stable Fragment · BPC Fragment 17-23
Frag 17-23 (HGH Fragment 17-23) is a 7-amino-acid sub-fragment of human growth hormone derived from the N-terminal region of the molecule. Distinct from the much better-known HGH Frag 176-191 (C-terminal lipolytic fragment), Frag 17-23 corresponds to the disulfide-loop region of GH and is researched for putative effects on glucose regulation rather than lipolysis.
Inject fasted morning. Reconstitute with bacteriostatic water; refrigerate. The compound is poorly characterized - approach experimentally, monitor blood glucose during early use, and have carbohydrate available in case of unexpected hypoglycemia.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Frag 17-23 mechanism of action is poorly characterized. The 17-23 region of human growth hormone falls within the small disulfide-loop near the N-terminus of the molecule. Proposed mechanisms in the limited literature include:
Hypoglycemic Action
Some reports suggest the fragment may reproduce a portion of GH's acute insulin-like / hypoglycemic effect (distinct from GH's broader insulin-antagonist action at higher doses). The mechanism is unclear and the effect size in any controlled study is unestablished.
No Receptor Identified
Unlike HGH Frag 176-191 (which acts via β3-adrenergic receptor), no specific receptor has been published for Frag 17-23. This is a major caveat - efficacy claims rest on a poorly-defined mechanism.
Short Plasma Half-Life
~30-60 minutes by analogy with other small HGH fragments. Daily dosing typical based on community protocols.
Not Met-Containing
The 17-23 sequence does not contain methionine, so the GHK-Cu chemistry conflict does not apply (unlike Frag 176-191).
What to expect
Week 1-2: minimal subjective effect; possible mild glucose changes.
Week 4-8: theoretical metabolic adaptation - effect size unknown in humans.
Week 8-12: cumulative effects difficult to attribute to the peptide vs other lifestyle factors.
Evidence
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Keep separate
Side effects & safety
Commonly reported
- Injection site reaction (mild)
- Possible mild hypoglycemia in fasted state
- Mild headache (early doses)
Less common & notes
- Hypoglycemia (more pronounced in users on insulin or sulfonylureas).
- Long-term safety completely uncharacterized - no human exposure outside research-chemical community use.
- Theoretical effects on GH/IGF-1 axis at high doses unknown.
- Allergic reaction to peptide rare.
- Given the sparse literature, side-effect surveillance relies on careful self-monitoring.
Pharmacokinetics
Storage. Lyophilized vial: refrigerate (2-8°C / 36-46°F) or freeze (-20°C) for long-term storage. After reconstitution with bacteriostatic water: refrigerate, use within 14-21 days. Light-sensitive. Do NOT shake. Discard if cloudy, discolored, or beyond use-by window.
Regulatory status
Not FDA-approved for any indication. Has not entered Phase 1 clinical trials. Available only as research chemical from peptide-supply vendors. Limited published literature beyond foundational biochemistry studies from the 1980s-90s. WADA prohibited under class S2 (peptide hormones, growth factors) by class effect. Sale for human use is prohibited by FDA regulation.
Put it to work
Calculate, log & track
Open Frag 17-23 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Frag 17-23 in the app →Go deeper
The guide & community
The complete Frag 17-23 walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗